---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069825"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T18:56:37.502054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025

## Summary
- Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.
- Cash $688.4M as of March 31, 2025; expected to fund operations into first half of 2028.
- BOND-003 Cohort C: 75.5% CR at any time; 24-month CR rate 42.3% by K-M; 97.3% progression-free at 24 months.
- Cohort P: 90.5% high-grade recurrence-free survival at 3 and 9 months in BCG-unresponsive Ta/T1 disease.
- Anticipates starting BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in H2 2025.

## SEC filing metadata
- accession: 0000950170-25-069825
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/0000950170-25-069825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/ck0001991792-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069825
- JSON: https://secwatch.observer/filing/0000950170-25-069825.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.